Y H.P.Acthar Gel
Reciente fué GILEAD... con Sovaldi
Ahora Roche se incorpora al Club...
In unusually blunt language, the U.K. agency that monitors the cost effectiveness of medicines has rebuked Roche over its refusal to lower the price of its Kadcyla breast cancer treatment. And as a result, the agency says it is unable to recommend the Roche drug is made available to patients.
Despite evidence that the drug helps patients, the approximate $150,000 price tag for an average 14 months of treatment makes it “impossible” to include in the U.K.’s National Health Service budget, according to the National Institute for Health and Care Excellence, the watchdog agency. Here is the analysis.
“Although Roche proposed a discount to the full list price of Kadcyla, it made little difference to its value for money, leaving it well above the top of our specially extended range of cost effectiveness for cancer drugs,” says Andrew Dillon, who heads the agency, in a statement.
“We are really disappointed that Roche were not able to demonstrate more flexibility to help us make a positive recommendation. The company is well aware that we could not have recommended Kadcyla at the price it proposed.” Roche had been warned last April that the Kadlyca price was too high.